Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Here is What Hedge Funds Think About Infinity Pharmaceuticals Inc. (INFI)

Page 1 of 2

Infinity Pharmaceuticals Inc. (NASDAQ:INFI) was in 22 hedge funds’ portfolio at the end of March. INFI investors should be aware of a decrease in activity from the world’s largest hedge funds in recent months. There were 22 hedge funds in our database with INFI positions at the end of the previous quarter.

In the financial world, there are plenty of methods market participants can use to watch publicly traded companies. A pair of the most useful are hedge fund and insider trading activity. At Insider Monkey, our research analyses have shown that, historically, those who follow the top picks of the elite fund managers can beat their index-focused peers by a significant margin (see just how much).

Infinity Pharmaceuticals Inc. (NASDAQ:INFI)Just as integral, optimistic insider trading activity is another way to parse down the financial markets. Obviously, there are many motivations for an executive to drop shares of his or her company, but just one, very obvious reason why they would buy. Plenty of academic studies have demonstrated the market-beating potential of this strategy if shareholders understand what to do (learn more here).

With all of this in mind, let’s take a look at the latest action encompassing Infinity Pharmaceuticals Inc. (NASDAQ:INFI).

How are hedge funds trading Infinity Pharmaceuticals Inc. (NASDAQ:INFI)?

In preparation for this quarter, a total of 22 of the hedge funds we track were bullish in this stock, a change of 0% from one quarter earlier. With hedge funds’ sentiment swirling, there exists an “upper tier” of key hedge fund managers who were boosting their stakes significantly.

Of the funds we track, OrbiMed Advisors, managed by Samuel Isaly, holds the largest position in Infinity Pharmaceuticals Inc. (NASDAQ:INFI). OrbiMed Advisors has a $161.4 million position in the stock, comprising 3.8% of its 13F portfolio. The second largest stake is held by Joseph Edelman of Perceptive Advisors, with a $133.3 million position; the fund has 16% of its 13F portfolio invested in the stock. Remaining hedgies with similar optimism include Daniel Gold’s QVT Financial, Julian Baker and Felix Baker’s Baker Bros. Advisors and Steven Cohen’s SAC Capital Advisors.

Because Infinity Pharmaceuticals Inc. (NASDAQ:INFI) has faced declining sentiment from the smart money, it’s easy to see that there lies a certain “tier” of funds who sold off their positions entirely last quarter. It’s worth mentioning that Sean Cullinan’s Point State Capital said goodbye to the largest position of all the hedgies we monitor, totaling close to $21.2 million in stock.. James E. Flynn’s fund, Deerfield Management, also dropped its stock, about $20.1 million worth. These moves are intriguing to say the least, as aggregate hedge fund interest stayed the same (this is a bearish signal in our experience).

How are insiders trading Infinity Pharmaceuticals Inc. (NASDAQ:INFI)?

Insider purchases made by high-level executives is at its handiest when the company we’re looking at has seen transactions within the past 180 days. Over the latest half-year time frame, Infinity Pharmaceuticals Inc. (NASDAQ:INFI) has seen zero unique insiders purchasing, and 4 insider sales (see the details of insider trades here).

Let’s also take a look at hedge fund and insider activity in other stocks similar to Infinity Pharmaceuticals Inc. (NASDAQ:INFI). These stocks are Incyte Corporation (NASDAQ:INCY), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Questcor Pharmaceuticals Inc (NASDAQ:QCOR), Charles River Laboratories (NYSE:CRL), and Theravance Inc (NASDAQ:THRX). This group of stocks are the members of the biotechnology industry and their market caps are closest to INFI’s market cap.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!